Join BJS Academy
BJS Academy>Randomized clinical ...>Event free survival ...
Normal View Dyslexic View

Event-free survival with pembrolizumab in early triple-negative breast cancer.

1 March 2022
Randomized clinical trials Breast
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

Use of neoadjuvant pembrolizumab plus chemotherapy, with additional pembrolizumab postoperatively improved event-free survival from 76.8 to 84.5 per cent at 36 months in this study that included 1174 women.

Comment: New standard of care?

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct238
Randomized clinical trials
Randomized clinical trials
Breast
Event-free survival with pembrolizumab in early triple-negative breast cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.N Engl J Med 2022; 386: 556-567.
01032022
Use of neoadjuvant pembrolizumab plus chemotherapy, with additional pembrolizumab postoperatively improved event-free survival from 76.8 to 84.5 per cent at 36 months in this study that included 1174 women.
Comment: New standard of care?
Published on: 1 March 2022
Article ID: rct238

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).

17 May 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!